^
Association details:
| Biomarker: | ROS1 G2032K |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Lorbrena (lorlatinib) (ALK inhibitor, ROS1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
A novel ROS1 G2032 K missense mutation mediates lorlatinib resistance in a patient with ROS1-rearranged lung adenocarcinoma but responds to nab-paclitaxel plus pembrolizumab
Published date:
03/26/2020
Excerpt:
ROS1 G2032 K is a novel mutation that mediates resistance to lorlatinib.
DOI:
10.1016/j.lungcan.2020.03.019
